Hypoxia imaging of uterine cervix carcinoma with 18F-FETNIM PET/CT

Clinical Nuclear Medicine

Volumn 37, Issue 11, 2012, Pages 1065-1068

  Vercellino, Laetitia ^a   Groheux, David ^a   Thoury, Anne ^a   Delord, Marc ^b   Schlageter, Marie Hélène ^c   Delpech, Yann ^a   Barré, Emmanuelle ^a   Baruch Hennequin, Valérie ^a   Tylski, Perrine ^a   Homyrda, Laurence ^c   Walker, Francine ^d   Barranger, Emmanuel ^a   Hindié, Elif ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b Universitary Institute of Hematology Paris VII   (France)

^c Departments of Cellular Biology   (France)

^d BICHAT HOSPITAL   (France)

Author keywords

18F FETNIM; hypoxia; PET CT; uterine cervical cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FLUOROERYTHRONITROIMIDAZOLE F 18; FUROSEMIDE; OSTEOPONTIN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE MARKER; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; HYPOXIA; LOG RANK TEST; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; UTERINE CERVIX CARCINOMA;

ADULT; AGED; ANOXIA; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGING, THREE-DIMENSIONAL; MIDDLE AGED; NITROIMIDAZOLES; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; UTERINE CERVICAL NEOPLASMS;

EID: 84867859567     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3182638e7e     Document Type: Article

References (21)

1. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007;26:225-239. (Pubitemid 47101660)
2. Hockel M, Schlenger K, Aral B, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996;56:4509-4515. (Pubitemid 26330463)
3. Rajendran JG, Hendrickson KR, Spence AM, et al. Hypoxia imaging-directed radiation treatment planning. Eur J Nucl Med Mol Imaging. 2006;33(suppl 1): 44-53.
4. Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002;53:12-22. (Pubitemid 34465802)
5. Knocke TH,Weitmann HD, Feldmann HJ, et al. Intratumoral PO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol. 1999;53:99-104.
6. Kappler M, Taubert H, Holzhausen HJ, et al. Immunohistochemical detection of HIF-1alpha and CAIX in advanced head-and-neck cancer. Prognostic role and correlation with tumor markers and tumor oxygenation parameters. Strahlenther Onkol. 2008;184:393-399.
7. Overgaard J, Eriksen JG, Nordsmark M, et al. Danish Head and Neck Cancer Study Group. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol. 2005;6:757-764. (Pubitemid 41430716)
8. Le QT, Sutphin PD, Raychaudhuri S, et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res. 2003;9:59-67. (Pubitemid 36109716)
9. Rajendran JG, Schwartz DL, O'Sullivan J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res. 2006;12:5435-5441. (Pubitemid 44497258)
10. Lewis JS, Laforest R, Dehdashti F, et al. An imaging comparison of 64Cu-ATSM and 60Cu-ATSMin cancer of the uterine cervix.JNuclMed. 2008;49:1177-1182. (Pubitemid 351948028)
11. Lehtiö K, Eskola O, Viljanen T, et al. Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2004;59:971-982. (Pubitemid 38834289)
12. Li L, Hu M, Zhu H, et al. Comparison of 18F-fluoroerythronitroimidazole and 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced nonYsmall-cell lung cancer. Clin Lung Cancer. 2010;11: 335-340.
13. Moretti JL, Schlageter M,Vercellino L, et al. Imaging of uterine cervix carcinoma using the hypoxia tracer 18F-FETNIM PET. J Nucl Med. 2010;51(suppl 2):21.
14. Eschmann SM, Paulsen F, Reimold M, et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in nonYsmall cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med. 2005;46:253-260. (Pubitemid 43073432)
15. Dietz DW, Dehdashti F, Grigsby PW, et al. Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum. 2008;51:1641-1648.
16. Chung HH, Nam BH, Kim JW, et al. Preoperative [18F]FDG PET/CT maximum standardized uptake value predicts recurrence of uterine cervical cancer. Eur J Nucl Med Mol Imaging. 2010;37:1467-1473.
17. Dehdashti F, Mintun MA, Lewis JS, et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging. 2003;30: 844-850. (Pubitemid 36734203)
18. Dehdashti F, Grigsby PW, Lewis JS, et al. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4- methylthiosemicarbazone). J Nucl Med. 2008;49:201-205. (Pubitemid 351225657)
19. Holland JP, Lewis JS, Dehdashti F. Assessing tumor hypoxia by positron emission tomography with Cu-ATSM. Q J Nucl Med Mol Imaging. 2009;53: 193-200.
20. Fedarko NS, Jain A, Karadag A, et al. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res. 2001;7: 4060-4066. (Pubitemid 34044628)
21. Bache M, Kappler M, Wichmann H, et al. Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients. BMC Cancer. 2010;10:132.